When did Novavax report Q1 2025 earnings?

Novavax (NVAX) reported Q1 2025 earnings on May 8, 2025 before market open.

What were Novavax's Q1 2025 revenue and EPS?

Novavax reported revenue of $666.7M and eps of $2.93 for Q1 2025.

Did Novavax beat estimates in Q1 2025?

Revenue beat the consensus estimate of $343.9M by $322.8M. EPS beat the consensus estimate of $0.71 by $2.22.

How did Novavax's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 610.3% from $93.9M a year earlier.

Where can I find Novavax's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0001000694-25-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.

Novavax NVAX Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue$666.7MBeat by $322.8M

EPS$2.93Beat by $2.22

Revenue estimate$343.9M

EPS estimate$0.71

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$52.1M

EPS estimate-$0.40

Financials

Q1 2025

Income statement

See full

Revenue$666.7M+610%

Gross profit$652.5M+1,783%

Operating income$515.5M+456%

Net income$518.6M+452%

EPS (diluted)$2.93+379%

Balance sheet

See full

Cash & equivalents$263.3M-45.2%

Total debt$58.5M-3.9%

Total equity-$75.6M+91.3%

Total assets$1.3B-4.5%

Cash flow

See full

Operating cash flow-$185.5M-122%

CapEx$1.6M-76.8%

Free cash flow-$187.1M-107%

Valuation & ratios

Valuation

as of 03/31/25

See full

Market cap$1.03B+54.1%

Enterprise value$826.21M+231%

P/E2.2×—

P/S0.8×+0.2×

Profitability

See full

Gross margin87.4%+24.5pp

Operating margin32.8%+21.2pp

Net margin38.1%+25.2pp

FCF margin-15.7%-6.4pp

Returns & leverage

See full

Current ratio2.1×+1.2×

Segments

By geography

See full

Rest of North America$143.9M—

Rest of the world$43.5M+341%

Europe$8.1M-91.1%

By segment

See full

Reportable Segment$666.7M+610%

By product

See full

Royalties-—

Versus estimates

Revenue

Q1 2026$139.5MBeat by $59.7M Q4 2025$147.1MBeat by $57.3M Q3 2025$70.4MMiss by $19.8M Q2 2025$239.2MBeat by $183.6M

Q1 2025$666.7MBeat by $322.8M

Q4 2024$88.3MBeat by $3.9M

Diluted EPS

Q1 2026-$0.06Beat by $0.19 Q4 2025$0.11Beat by $0.77 Q3 2025-$0.62Beat by $0.46 Q2 2025$0.62Beat by $0.69

Q1 2025$2.93Beat by $2.22

Q4 2024-$0.51Beat by $0.24

Ask the moment Novavax reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Novavax report Q1 2025 earnings?: Novavax (NVAX) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Novavax's Q1 2025 revenue and EPS?: Novavax reported revenue of $666.7M and eps of $2.93 for Q1 2025.
Did Novavax beat estimates in Q1 2025?: Revenue beat the consensus estimate of $343.9M by $322.8M. EPS beat the consensus estimate of $0.71 by $2.22.
How did Novavax's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 610.3% from $93.9M a year earlier.
Where can I find Novavax's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0001000694-25-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.